To determine the effects of an exercise program on fatty liver disease and metabolite markers of cardiometabolic health.
Aims:
To determine the effects of an exercise program on fatty liver disease and metabolite markers of cardiometabolic health.
Methods: 42 apolipoprotein E knockout mice fed on a highfat diet (HFD) were randomized: 16 were administered the diet for 12 weeks. 10 mice took the HFD for 26 weeks (late control); and 16 mice took the diet for 16 weeks and underwent exercise for 10 weeks (late exercise). For the human study, 55 males with mean age 21 ± 3 years and mean BMI 24.4 ± 2.73 kg/m 2 underwent an 80-day exercise programme. 10 L plasma from mice and humans was subjected to metabolomic analysis using LC-MS/MS.
Results:
We found increased circulating serotonin metabolites in both mice (late exercise vs late control) and men (p < 0.05). Intriguingly, the endocannabinoid anandamide, purported to be responsible for the "runner's high", was significantly increased in HFD exercising mice (p = 0.01). Liver fat measured by total triglyceride content was significantly decrease in HFD exercise mice (p < 0.05). Several metabolic pathways were changed by exercise in humans undergoing the exercise programme. A microbiome-derived tryptophan metabolite (p = 9.4 × 10 −6 ) was also significantly elevated by exercise. Acetylcholine, a marker of neuromuscular fatigue, was decreased post exercise compared to baseline (p = 0.008), as was arginine (p < 0.0001) -the major substrate of NOS. Several plasma non-essential amino acids were also elevated in humans post exercise program.
Conclusion: Exercise reduces liver fat and reveals plasma markers of improved psychological, physiological, vascular, and metabolic health. Methods: Retrospective analysis of adults undergoing elective surgery from 01/01/2017-01/04/2018 who received antiplatelets pre-operatively. Compliance with ESC Guidelines was rated according to thrombosis and bleeding risk factors.
Results: Evaluated 182 patients, age 69 ± 12 years. Interrupting antiplatelets was compliant in 76.4%, duration of cessation was compliant in 26.4%. No difference between antiplatelet type/combinations and compliance was found. Of the 134 non-compliant patients, 73.1% had antiplatelets ceased later than advised. Aspirin cessation was closer to surgery than advised (80.3%, p = 0.027) and associated with increased bleeding (83.1%, p = 0.004). Clopidogrel monotherapy was associated with reduced bleeding (33.3%, p = 0.017). Less bleeding occurred in patients with gastro-oesophageal reflux disease: 17/26 (65%) vs 54/64 (84%) (p = 0.046). Cardiac surgery was associated with increased bleeding (89.0%, p < 0.001) despite higher compliance for interrupting or continuing antiplatelets (85.4%, p < 0.01). Thromboembolism occurred in 2 (1.1%), transfusion in 32 (17.6%), and 14 (7.7%) required rehospitalisation within 3 months.
Conclusion: There is considerable compliance with recommendations regarding interruption/continuation of antiplatelets, but widespread discordance concerning duration of antiplatelet interruption, suggesting requirements for further Guideline dissemination/education. 
